Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01222351 · ClinicalTrials.gov registry record · NA
Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172
A NA study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- NA
- Development phase
- 161
- Enrollment target
NCT01222351 is a NA study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 161 participants.
The verdict
NCT01222351, a NA study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 161 participants
- Enrollment target
Study Summary
The overall goal of this project is to establish and validate biomarkers associated with the risk and progression of late onset Alzheimer's disease, mild cognitive impairment and cognitive decline. The investigators will use baseline and longitudinal measurements of plasma amyloid beta-40 and amyloid beta-42 to investigate the risk of developing mild cognitive impairment and late onset Alzheimer's disease, as well as the rates of cognitive decline and Alzheimer's disease progression. The driving hypothesis of the study is that amyloid beta in the brain as measured by positron emission tomography positivity is associated with the onset of cognitive decline associated with late onset Alzheimer's disease.
Interventions
- DRUG BAY 94-9172 (Florbetaben)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2010-12 |
| Est. Completion | 2014-10-22 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01222351
The ClinicalTrials.gov registry entry for NCT01222351 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BAY 94-9172 (Florbetaben) is the first listed.
NCT01222351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01222351 about?
NCT01222351 is a clinical study titled "Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172". The overall goal of this project is to establish and validate biomarkers associated with the risk and progression of late onset Alzheimer's disease, mild cognitive impairment and cognitive decline. The investigators will use baseline and longitudinal measurements of plasma amyloid beta-40 and amyloi...
What is the current status of trial NCT01222351?
This trial is currently completed. It is a NA study. The enrollment target is 161 participants. The study started on 2010-12. Estimated completion is 2014-10-22.
What interventions are being tested in trial NCT01222351?
The interventions under investigation include: BAY 94-9172 (Florbetaben) (DRUG).
Who is sponsoring clinical trial NCT01222351?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.